HopeStage
Back to all studies
RecruitingNCT07467993

GXV813 for acute schizophrenia symptoms

About this titleRead the official source — NCT07467993

Researchers are comparing GXV813 and placebo to find out how the approaches affect psychotic symptoms in adults with schizophrenia.

Medication studyAges 18–65United States + Bulgaria
The study in practice

Understand this study

What is this study about?

Researchers are comparing GXV813 and placebo to find out how the approaches affect psychotic symptoms in adults with schizophrenia.

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
Bentonville and 15 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: March 16, 2026
Recruitment status
Recruiting
Enrollment listed in the registry
142
Sponsor
Novartis Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Bulgaria
Age range
From 18 Years to 65 Years
Official registry ID
NCT07467993
Official title
Show the full official title

A Phase 2a, Randomized, Participant- and Investigator- Blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With DSM-5 Schizophrenia (STAR-1)

Recruitment & locations

Currently recruiting

Bentonville, United States · Pico Rivera, United States · Miami, United States

11 more locations
  • Decatur, United States
  • Chicago, United States
  • St Louis, United States
  • Sofia, Bulgaria
  • Haskovo, Bulgaria
  • Kazanlak, Bulgaria
  • Lovech, Bulgaria
  • Plovdiv, Bulgaria
  • Sliven, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Vratsa, Bulgaria

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing GXV813 and placebo to find out how the approaches affect psychotic symptoms in adults with schizophrenia.

Who is behind this study?

The study sponsor is Novartis Pharmaceuticals.

Does this study involve medication?

Yes. The study involves medication, including GXV813 and Placebo.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies